These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 26983548)

  • 1. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
    Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
    Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature.
    Mechler K; Häge A; Schweinfurth N; Glennon JC; Dijkhuizen RM; Murphy D; Durston S; Williams S; K Buitelaar J; Banaschewski T; Dittmann RW; Tactics Consortium T
    Z Kinder Jugendpsychiatr Psychother; 2018 May; 46(3):246-263. PubMed ID: 28922069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
    Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
    BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Feusner JD; Kerwin L; Saxena S; Bystritsky A
    Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).
    Haghighi M; Jahangard L; Mohammad-Beigi H; Bajoghli H; Hafezian H; Rahimi A; Afshar H; Holsboer-Trachsler E; Brand S
    Psychopharmacology (Berl); 2013 Aug; 228(4):633-40. PubMed ID: 23525525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
    Aboujaoude E; Barry JJ; Gamel N
    J Clin Psychopharmacol; 2009 Feb; 29(1):51-5. PubMed ID: 19142108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fronto-Striatal Glutamate in Autism Spectrum Disorder and Obsessive Compulsive Disorder.
    Naaijen J; Zwiers MP; Amiri H; Williams SCR; Durston S; Oranje B; Brandeis D; Boecker-Schlier R; Ruf M; Wolf I; Banaschewski T; Glennon JC; Franke B; Buitelaar JK; Lythgoe DJ
    Neuropsychopharmacology; 2017 Nov; 42(12):2456-2465. PubMed ID: 27869141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COMPULS: design of a multicenter phenotypic, cognitive, genetic, and magnetic resonance imaging study in children with compulsive syndromes.
    Naaijen J; de Ruiter S; Zwiers MP; Glennon JC; Durston S; Lythgoe DJ; Williams SC; Banaschewski T; Brandeis D; Franke B; Buitelaar JK
    BMC Psychiatry; 2016 Oct; 16(1):361. PubMed ID: 27782808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.
    Stewart SE; Jenike EA; Hezel DM; Stack DE; Dodman NH; Shuster L; Jenike MA
    J Clin Psychopharmacol; 2010 Feb; 30(1):34-9. PubMed ID: 20075645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine as treatment for compulsivity in child and adolescent psychiatry: Descriptive findings from an incompleted randomized, double-blind, placebo-controlled trial.
    Niemeyer L; Mechler K; Dittmann RW; Banaschewski T; Buitelaar J; Durston S; Häge A
    Contemp Clin Trials Commun; 2022 Oct; 29():100982. PubMed ID: 36092975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension.
    Aman MG; Findling RL; Hardan AY; Hendren RL; Melmed RD; Kehinde-Nelson O; Hsu HA; Trugman JM; Palmer RH; Graham SM; Gage AT; Perhach JL; Katz E
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):403-412. PubMed ID: 26978327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
    Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E
    J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
    Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
    J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial.
    Farnia V; Gharehbaghi H; Alikhani M; Almasi A; Golshani S; Tatari F; Davarinejad O; Salemi S; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S
    J Psychiatr Res; 2018 Sep; 104():137-143. PubMed ID: 30044966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine augmentation for refractory obsessive-compulsive disorder.
    Pasquini M; Biondi M
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1173-5. PubMed ID: 16730870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials.
    Scahill L; Sukhodolsky DG; Anderberg E; Dimitropoulos A; Dziura J; Aman MG; McCracken J; Tierney E; Hallett V; Katz K; Vitiello B; McDougle C
    Autism; 2016 Feb; 20(2):145-52. PubMed ID: 25882391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
    Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA
    JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial.
    Maraone A; Trebbastoni A; Di Vita A; D'Antonio F; De Lena C; Pasquini M
    JMIR Res Protoc; 2023 May; 12():e39223. PubMed ID: 37166948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.
    Modarresi A; Chaibakhsh S; Koulaeinejad N; Koupaei SR
    Psychiatry Res; 2019 Dec; 282():112602. PubMed ID: 31630042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial.
    Reddihough DS; Marraffa C; Mouti A; O'Sullivan M; Lee KJ; Orsini F; Hazell P; Granich J; Whitehouse AJO; Wray J; Dossetor D; Santosh P; Silove N; Kohn M
    JAMA; 2019 Oct; 322(16):1561-1569. PubMed ID: 31638682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.